MENGMENG LIU

MENGMENG LIU

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2026 in Clinical Cancer Research
Verified
Journal Article
Closed access
ZTZhichao Tan
Zhichao Tan
JRJiayin Ruan
Jiayin Ruan
YWYan Wu
Yan Wu
ZFZhengfu Fan
Zhengfu Fan
CBChujie Bai
Chujie Bai
JLJiayong Liu
Jiayong Liu
Purpose: Alveolar soft part sarcoma (ASPS) is an ultrarare soft tissue sarcoma. Current standard therapy with PD-1/PD-L1 inhibitors achieves limited response rates (<40%). Lymphocyte-activation gene 3 (LAG-3) is coexpressed with PD-1 on exhausted T cells, and dual blockade has shown synergy in some solid tumors but remains unexplored in sarcoma. This trial evaluated the efficacy of IBI110 (anti–LAG-3) plus sintilimab (anti–PD-1) in advanced ASPS. Patients and Methods: This open-label, phase II study enrolled 28 patients from July 2022 to September 2023 (median follow-up, 33.6 months). Both drugs were given intravenously at 200 mg every 3 weeks. The primary endpoint was overall response rate (ORR) by RECIST v1.1. Results: Among 28 patients, 8 (28.6%) were resistant to prior immune checkpoint inhibitors (ICI), and 20 (71.4%) were ICI-naïve. The overall ORR was 51.8% (14/27 evaluable), including 4 complete responses and 10 partial responses. During a median follow-up of 33.6 months, the median progression-free survival (PFS) and overall survival (OS) were not reached in the whole population. In ICI-naïve patients, the ORR was 60%, with median PFS/OS not reached. In ICI-resistant patients, the ORR was 25%, with median PFS of 14.9 months and median OS of 25.4 months. The median time to response was 3.3 months; the median duration of response (DoR) was not reached. Grade 3 to 4 treatment-related adverse events occurred in nine patients (32.1%), with no treatment-related deaths. Exploratory analysis showed that responders had significantly higher baseline LAG-3+ cell density in tumor specimens. Conclusions: Dual LAG-3/PD-1 blockade demonstrated promising and durable antitumor activity with manageable safety in both ICI-naïve and ICI-resistant advanced ASPS, warranting further investigation.

2 October 2026 in Cancers
Verified
Journal Article
Open access
PDF file
ZTZhichao Tan
Zhichao Tan
YSYue Sun
Yue Sun
YZYunxiao Zhang
Yunxiao Zhang
ZFZhengfu Fan
Zhengfu Fan
CBChujie Bai
Chujie Bai
JLJiayong Liu
Jiayong Liu
Background/Objectives: The anatomical distribution of inguinal lymph node (ILN) metastases may inform research on the extent of therapeutic dissection for lower-limb melanoma. Methods: Fifty-eight patients undergoing radical inguinal lymph node dissection (rILND) were retrospectively evaluated using five anatomical zones. Zone-specific node counts were reaggregated, and exploratory binary logistic regression assessed multiple-zone involvement. Results: The cohort included 48 clinically node-positive and 10 sentinel lymph node biopsy (SLNB)-positive patients. Among 816 mapped ILNs, 149 were positive. Zone I contained 102/149 positive nodes (68.5%); within-zone positivity was 102/303 (33.7%) in zone I, 27/243 (11.1%) in zone II, 13/190 (6.8%) in zone III, 3/39 (7.7%) in zone IV, and 4/41 (9.8%) in zone V. Five patients had no positive mapped ILNs. Zone I contained the only positive node in 19/20 patients (95.0%) and was the sole involved zone in 32/33 patients with single-zone involvement (97.0%). Twenty patients had multiple-zone involvement. In a two-variable complete-case model (50 patients; 18 events), ≥3 positive ILNs remained associated with multiple-zone involvement (adjusted odds ratio, 34.80; 95% confidence interval, 5.88–206.08), whereas extranodal extension did not. Conclusions: This small, selected cohort provides preliminary pathological evidence of preferential inferior-zone involvement. It does not establish sequential spread or the oncological safety of reduced rILND. External and prospective validation are required.



2 November 2026
Verified
Other
Open access
ZTZhichao Tan
Zhichao Tan
JRJiayin Ruan
Jiayin Ruan
YWYan Wu
Yan Wu
ZFZhengfu Fan
Zhengfu Fan
CBChujie Bai
Chujie Bai
JLJiayong Liu
Jiayong Liu
The Efficacy of IBI110 plus Sintilimab and Subsequent Therapies

2 November 2026
Verified
Other
Open access
ZTZhichao Tan
Zhichao Tan
JRJiayin Ruan
Jiayin Ruan
YWYan Wu
Yan Wu
ZFZhengfu Fan
Zhengfu Fan
CBChujie Bai
Chujie Bai
JLJiayong Liu
Jiayong Liu
Representative immunohistochemistry images of each immune cells. (A) CD3; (B) CD4; (C) CD8; (D) CD20; (E) PD1; (F) PD-L1